Press Room

Press Release / Nov 16, 2023

Hovione acquires ExtremoChem and its portfolio of proprietary sugars to support customers with stabilization and delivery of biopharmaceuticals

Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, today announced it has acquired ExtremoChem Lda (ExtremoChem)

scientist working with a microscope | Hovione
  • Hovione has acquired ExtremoChem Lda, a start-up company with a portfolio of rare sugars, synthetic analogues of the natural molecules found in extremophiles.
  • The acquisition provides Hovione with new high-performance functional materials, which have shown potential in stabilizing biopharmaceuticals.

Lisbon, November 16, 2023, Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, today announced it has acquired ExtremoChem Lda (ExtremoChem), an innovative start-up company focused on the synthesis, development, and commercialization of bio-inspired synthetic sugars, targeting enhanced stabilization, reduced viscosity and delivery performance of proteins and other biopharmaceuticals. 

ExtremoChem developed a library of proprietary sugars, synthetic analogues of natural molecules found in extremophiles – organisms capable of withstanding the most uninhabitable environments. These sugars have shown potential in overcoming challenges associated with the stabilization of biopharmaceuticals during production, purification, formulation, and transportation.

Dr. Jean-Luc Herbeaux, Hovione’s CEO commented: "Proteins and other biopharmaceuticals account for a significant share of our customers ´pipelines.  The acquisition of ExtremoChem’s synthetic sugars combined with Hovione's particle engineering capabilities provides our customers with a unique set of tools to optimize formulations that address stability issues encountered during the life cycle of biopharmaceuticals.”

Filipe Aguiar, ExtremoChem’s Managing Director commented: “I am delighted that ExtremoChem has been acquired by Hovione. Hovione has a long history of developing and industrializing innovative technologies for the pharma industry. This acquisition will help ensure that the science we developed at ExtremoChem will have a wider and faster market adoption.”

The announcement of this acquisition demonstrates Hovione´s commitment to expand its technology platforms. The company is investing both in new assets and innovative technologies to meet customer demand for integrated and differentiated development and manufacturing services in drug substance, particle engineering and drug product.
 

About Hovione
Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. 

Hovione's culture is based on innovation, quality, and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.
 

About ExtremoChem
ExtremoChem is a chemical synthesis start-up company focused on the development of organic synthetic sugars for the stabilization of biologicals under stress conditions. 

 

 

Also in the Press Room

See All

With more than six decades of experience in pharmaceutical development and manufacturing, Hovione is an international CDMO offering a comprehensive range of services for New Molecular Entities (NMEs), including drug substances, intermediates, and drug products. The company also supplies niche generic APIs and delivers advanced technologies supporting multiple drug delivery platforms, including oral, injectable, inhalation, and topical formulations.  Today, Hovione employs 2,500 people worldwide and operates 900 m3 of manufacturing capacity across four sites in Europe, the U.S. and Asia. Japan has played an important role in the company’s global strategy since its early years. Initial export activities were followed in 2017 by the establishment of a Japanese subsidiary in Osaka.   Read the full article in Japanese at Yakuji.co.jp Read the article translated in English  

Press Clipping
Yakuji Nippo Magazine, 13 March 2026

International CDMO strengthens its presence in Japan: from active pharmaceutical ingredients to formulations, all at the same location

Mar 13, 2026

In an interview with Executiva, a portuguese media outlet focused on women´s leadership, Diane Villax, co-founder and long-standing leader of Hovione, reflects on her journey and the company’s development over more than six decades. Diane Villax’s career began at a time when few women worked outside the home. At 19, she joined a trading company as a foreign languages correspondent, where she developed essential business skills — including commercial correspondence, banking and export procedures — that later proved instrumental in helping her husband, Ivan Villax, establish Hovione in 1959. From its earliest days operating in the family home in Lisbon, Hovione adopted an international outlook. The company’s first major customers were in Japan, setting demanding quality standards that helped shape its long-term position in global markets. Over the following decades, Hovione expanded its footprint with the construction of its first manufacturing site in Loures (1969), followed by expansion to Macau (1986), the United States (New Jersey, early 2000s) and Ireland (Cork). The company grew into a global organization with more than 2,500 employees — including over 300 scientists — and a reputation as a preferred supplier to leading pharmaceutical companies worldwide. Throughout the interview, Diane highlights the values that have guided the company’s development: a commitment to excellence, a strong work ethic, and a focus on quality and long-term relationships. Although she did not have formal business training, she learned “on the job” and brought discipline, precision and structure to her role — particularly in the company’s early financial and administrative leadership. Now in her nineties and an active member of Hovione’s Board of Directors, Diane Villax remains engaged with the company’s evolution and governance, reflecting a continued commitment to its long-term development. Her story reflects entrepreneurial drive, resilience and long-term leadership — and offers insight into the values that have shaped Hovione’s trajectory for more than six decades. Read the full interview at Executiva.pt (in portuguese).    

Article
Executiva, 23 February 2026

Hovione’s Diane Villax: “I was not brought up to be a business woman”

Feb 23, 2026

Márcio Temtem, vice president, Strategic Business Management, Hovione, addresses molecule complexity, speed, and regionalization via integrated manufacturing. The landscape of small molecule manufacturing is rapidly evolving, according to Márcio Temtem, vice president, Strategic Business Development, Hovione, who provides an expert look into how his firm is evolving their approach as the industry changes. With 17 years of experience at Hovione, a family-owned CDMO with a 66-year legacy, Temtem identifies three pivotal trends currently shaping the industry: increased complexity, accelerated development speed, and the regionalization of supply chains. Temtem observes that small molecules have grown significantly in size and complexity, often requiring multiple chemical steps and high-potency handling. This shift necessitates a specialized "toolbox" to overcome modern bioavailability challenges. Highlighting Hovione's technical approach to these hurdles, Temtem states, "We use a platform called amorphous solid dispersions, produced by spray drying to address this challenge of bioavailability.” This platform represents a core area in which Hovione maintains global leadership, utilizing innovative tools to scale processes efficiently while minimizing the use of APIs. Temtem also mentions the increased influence of AI in drug discovery and deployment, which requires CDMOs to bridge the gap from grams to tons at a much faster pace than in previous years. He further addresses the trend of regionalization, noting the rise of countries such as the US and China prioritizing regional supply chain strategies. He explains that Hovione is uniquely positioned to navigate these new challenges with supply chains through its FDA-inspected sites across three continents. Central to Hovione’s competitive advantage is their integrated manufacturing offer, which combines drug substance and drug product expertise at a single location. Temtem emphasizes the value of this model, stating, “The company… has been investing in an integrated offer, bridging the problems of chemists and formulators all at the same shop.” To support this integration, the company continues to pioneer advanced manufacturing avenues, including continuous flow for drug substances and continuous tableting for drug products. Watch the full video interview or read the transcript at PharmTech.com  

Article
PharmTech, 6 February 2026

Hovione’s Strategy for Complexity, Speed, and Regional Supply Chains

Feb 06, 2026

Also in Events

See All